432 Nemvaleukin alfa, a novel engineered IL-2 cytokine, in combination with the anti-PD-1 antibody pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma (ION-01 study)

• Yan Wang,
• Manish Patel,
• Marshall Posner,
• Leonard D’Amico,
• Steven Fling,
• Brian Gastman,
• Mac Cheever,
• Cesar Perez,
• Yangchun Du,
• Conor Steuer,
• Jessica Geiger,
• Zujun Li,
• Angela Shaulov Kask,
• Derek Matthies,
• Sung Jin Huh,
• Julie Graham,
• Laura Chow

Affiliations

Yan Wang

China Medical University, Shenyang, Liaoning, China

Manish Patel

General Medicine, University Hospital Wishaw, Wishaw, UK

Marshall Posner

Aff155 grid.416167.3Icahn School of Medicine at Mount Sinai, Mount Sinai Medical Center New York NY USA

Leonard D’Amico

Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Steven Fling

Aff233 grid.34477.330000000122986657University of Washington Seattle WA USA

Brian Gastman

Department of Plastic Surgery, Cleveland Clinic, Cleveland, Ohio, USA

Mac Cheever

Aff7 0000 0001 2180 1622grid.270240.3Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center Seattle WA USA

Cesar Perez

1University of Miami Miller School of Med, Miami, FL, USA

Yangchun Du

9Alkermes, Inc., Waltham, MA, USA

Conor Steuer

Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, Georgia, USA

Jessica Geiger

5Cleveland Clinic Main Campus, Cleveland, OH, USA

Zujun Li

6Perlmutter Cancer Center at NYU, New York, NY, USA

Angela Shaulov Kask

2Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Derek Matthies

9Alkermes, Inc., Waltham, MA, USA

Sung Jin Huh

9Alkermes, Inc., Waltham, MA, USA

Julie Graham

9Alkermes, Inc., Waltham, MA, USA

Laura Chow

10University of Texas Austin, Austin, TX, USA